Ruey-ching (Richard) Hwang, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
Ruey-ching (Richard) Hwang, PhD
Dec 1, 2008

Ruey-ching (Richard) Hwang, PhD
Senior Director,
Pharmaceutical Sciences
Pfizer Global R&D

Richard (Ruey-ching) Hwang is senior director of clinical supply manufacturing at Pfizer and has been with the company since 2003. He previously held positions at Pharmacia, Mallinckrodt, and G.D. Searle.

Hwang has authored and/or coauthored nearly 20 papers, given nearly 40 presentations and training courses, and presented more than 20 posters at poster sessions. He is a member of the American Association of Pharmaceutical Scientists (AAPS) and is a member of Pharmaceutical Technology’s Editorial Advisory Board.

He holds an MBA from the Keller Graduate School of Management at DeVry University and a PhD in Pharmaceutics from the College of Pharmacy at the University of Iowa. He received his BS in Pharmacy from the School of Pharmacy, College of Medicine, National Taiwan University.

ADVERTISEMENT

post a comment
Please complete the form below to post your comment.
Bold = Required
Email Address Your email address will NOT be published.
Display Name appears with your comment
City
State
Country
Remember me: YesNo
Comment read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
39%
The US economic recovery
14%
Improved credit and financing flow to the small to emerging pharma/bio sector
15%
Less restrictive inventory control by pharmaceutical companies
8%
The level of competition from contract manufacturers in emerging markets
24%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
Federal Spending Freeze Could Threaten Supply-Chain Security

FindPharma Custom Search
Featured Jobs

More Jobs

12/1/2008
Click here